At Aurigene, we have the world-class infrastructure to provide end-to-end services (from discovery through commercialization) to our clients. We operate state-of-the-art R and D and manufacturing facilities that are audited by major international regulatory agencies. The R and D facilities are in Hyderabad and Bangalore with a total built area of over 300,000 Sq.m. This facility is equipped with multiple fume hoods and special-purpose labs such as:
Peptide laboratory Oligonucleotide laboratory High potent laboratory Kilo labs for scale-up
The R and D facilities also house state-of-the-art analytical infrastructure and safety study labs. We have access to 8 cGMP API manufacturing sites with over thousands of kilo liter capacity. Our manufacturing facilities can handle a variety of unit operations and multiple technologies such as steroids, peptides, high potent APIs, carbohydrates and mPEGs.
We operate our facilities by international sustainability frameworks and our efforts in sustainability are recognized by DJSI (Dow Jones Sustainability Indices), FTSE4Good Index, CDP (Carbon Disclosure Project), S&P BSE Carbonex, S&P BSE Greenex, Bloomberg Gender-Equality Index
Resources
SEPTEMBER 04, 2023
Why meet us at CPHI Barcelona?
Discover the Opportunities: Visit Aurigene Pharmaceutical Services at CPHI BarcelonaThe Contract Research, Development and Manufacturing Organization (CRDMO) industry is a dynamic and rapidly evolving sector emerging as it plays a vital role in providing a wide range of services enabling drug companies to bring their products to market efficiently and effectively...
Read More
Immuno Oncology - Therapies and Challenges
With more than 200 distinct cancer types recognized and steady increase in cancer incidence rates, the fight with cancer takes a new shape with each emerging decade. First was surgery, followed by radiotherapy and chemotherapy. The fourth one was targeted cancer therapeutics, also known as precision therapies. Precision therapies were established with the discove...
Read More
Anti-Infective Drug Discovery
Objective & Challenges: Objective was to identify an optimized anti-bacterial lead molecule with in vivo efficacy in relevant infection models an acceptable safety profile, and a patentable series. Challenge was to develop a more efficacious compound than the reference standard.Study design: Compounds were designed and synth...
Read More
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market